Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) News
Filter AVDL News Items
AVDL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AVDL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AVDL News From Around the Web
Below are the latest news stories about AVADEL PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate AVDL as an investment opportunity.
Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...Avadel Pharmaceuticals PLC (AVDL) reports significant revenue increase and outlines optimistic projections for 2025 amidst market expansion challenges. |
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of $240 – $260 million in 2025, representing 50% year-over-year growth at the midpoint -- -- Management to host a conference call today at 4:30 p.m. ET -- DUBLI |
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in ac |
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visitin |
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More StockInvestors who take an interest in Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) should definitely note that the... |
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges – DUBLIN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of combined findings from a social media analysis and a survey of people with narcolepsy taking twice-nightly sodium oxybate. Results showed that these indi |
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsAvadel Pharmaceuticals ( NASDAQ:AVDL ) Third Quarter 2024 Results Key Financial Results Revenue: US$50.0m (up by... |
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceDUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com |
Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ...Avadel Pharmaceuticals PLC (AVDL) reports robust Q3 performance with $50 million in net revenue and strategic expansions in patient care and market reach. |
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter -- -- Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy, granted ODE through October 16, 2031 -- -- LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA’s determination that LUMRYZ is clinically superior to twice-nightly oxybate products - |